The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation

• DOI: 10.1046/j.1365-2141.2001.02827.x
• Publication Date: 2003-03-11T06:34:18Z
• Authors: Valerio De Stefano; Ida Martinelli; Pier Mannuccio Ma...; Katia Paciaroni; Elena Rossi; Patrizia Chiusolo; Ida Casorelli; Giuseppe Leone
• Keywords: Factor V

The G20210A mutation in the prothrombin gene is associated with an increased risk of a first venous thromboembolic episode; few data are available about long‐term for recurrent thromboembolism and it not known whether or carriers should be recommended lifelong anticoagulant treatment after thrombosis. We investigated 624 patients, referred previous objectively documented deep thrombosis legs pulmonary embolism, to determine heterozygous episode thromboembolism. After exclusion other inherited (anti‐thrombin, protein C, S deficiency factor V Leiden) acquired (anti‐phospholipid antibody syndrome) causes thrombophilia, 52 were compared 283 patients normal genotype. relative was calculated between groups using Cox's proportional hazard model. had spontaneous similar that genotype (hazard ratio 1·3; 95% CI, 0·7–2·3). circumstances event (spontaneous secondary) did produce any substantial variation recurrence. In conclusion, treated oral anticoagulants length time as